Boundless Bio raises $105M in effort to reimagine targeted cancer therapy
Boundless Bio CEO Zach Hornby was sitting in his La Jolla, CA office last fall, preparing for a board meeting when his computer pinged with an email. It was his CSO, Chris Hassig, emailing over tables and charts at the best possible time.
Their new type of cancer treatment was working. In mice, at least.
“This was a catalytic event,” Hornby told Endpoints News. The data “really said, ‘yes, we can do this.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.